Status:
RECRUITING
Evaluating a Our Practice Advisory (OPA) to Optimize Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) Test Orders
Lead Sponsor:
University of California, Los Angeles
Conditions:
Physician Workflow
Resource Utilization
Eligibility:
All Genders
Phase:
NA
Brief Summary
Our Practice Advisory (OPA) are essential tools in clinical decision-making. The alerts are designed to guide providers towards evidence-based practices and improve patient outcomes. The focus of this...
Detailed Description
The purpose of this Quality Improvement (QI) initiative is to evaluate the impact of a randomized Our Practice Advisory (OPA) intervention on physician ordering behavior of Hemoglobin A1c (A1c) and Th...
Eligibility Criteria
Inclusion
- 18 years or older
- Inpatient or observation stays within UCLA Health System hospitals
- Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) ordered, AND this lab was ordered and resulted within the prior 30 days
Exclusion
- Have an A1c or TSH ordered and do not have a result for one of these labs in the prior 30 days
Key Trial Info
Start Date :
May 6 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
384 Patients enrolled
Trial Details
Trial ID
NCT06993805
Start Date
May 6 2025
End Date
February 1 2026
Last Update
May 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA Health System
Los Angeles, California, United States, 90024